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Blood Doping
Effects of blood withdrawal and reinfusion on
biomarkers of erythropoiesis in humans:
Implications for anti-doping strategies
To discriminate autologous blood doping proce-
dures from normal conditions, we examined the
hematological response to blood withdrawal and
reinfusion. We found that biomarkers of erythro-
poiesis are primarily affected in the anemic period.
Therefore, individual variations in [Hb] exceeding
15% between samples obtained shortly before any
major competition would be indicative of autolo-
gous blood manipulation.
Haematologica 2006; 91:1006-1008
(http://www.haematologica.org/journal/2006/07/1006.html)
Infusion of red blood cells in man to enhance oxygen
carrying capacity of blood is a known practice since the
1947.1 The release of recombinant human erythropoietin
(rHu-EPO) most likely replaced blood transfusion prac-
tices since rHu-EPO was found to be more efficient and
easy to manage by non-medical personnel. In year 2000,
a urine test for rHu-EPO became available, which provid-
ed a means for detecting its illegal used.2 Recently, ath-
letes have been tested positive for allogeneic blood trans-
fusion by means of flowcytometry3 indicating a return to
former blood transfusion practices. However, an
unequivocal detection method revealing autologous
transfusion is still not available. 
Since accelerated or inhibited erythropoiesis leads to
characteristic changes in peripheral blood parameters,
irrespectively of the stimulating agent, an indirect detec-
tion method of rHu-EPO use based on changes in certain
hematological parameters4 has been implemented by
some international sport federations. Despite its use, data
on the effect of blood withdrawal and reinfusion in these
hematological parameters have never been reported in
full. We hypothesize that autologous blood manipula-
tions produce large variations in currently used biomark-
ers of erythropoiesis making individual hematological
profiles an effective tool identifying this manipulation.
We measured hemoglobin concentration [Hb], hemat-
ocrit, reticulocytes, serum EPO and sTfR concentrations
in 10 healthy, male subjects at baseline and after the
withdrawal of 20±3% (1.3±0.2 L; mean±SEM) of the sub-
jects’ blood volume on day 0, 1, 3, 7 14, 21 and 28 and
after reinfusion of 0.8±0.1 L of packed RBCs on day 0, 1,
3, 7, 14 and 21. To maintain blood volume after blood
withdrawal, 1.3 L of hydroxyl-ethyl-starch (Voluven®)
was infused. All subjects were given daily oral iron sup-
plementation (100 mg). [Hb], hematocrit, reticulocytes
was measured using an automatic hematology system
(ADVIA 120, Bayer Diagnostics). Serum EPO and sTfR
concentrations were determined by ELISA (R&D systems
Inc.). The indirect OFF-hr blood models for rHu-EPO
detection were applied.4 A one-way ANOVA for repeat-
ed measurements was used to test for differences
between control values and samples taken during the
anemic and polycytemic phase.
We found that following blood withdrawal, [Hb]
remained reduced on average by ~15% for 2 weeks
(Table and Figure 1). Accordingly, s-EPO increased 4-fold
within a day, declining exponentially thereafter.
Reticulocyte count increased rapidly by 2.4-fold after 7
days, remaining elevated for another 7 days whereas
sTfR increased by 60% by day 14 and remained elevated
until 3 days after blood reinfusion. 
Following blood reinfusion, [Hb] increased acutely by
8% returning to the initial baseline value after 2 days. s-
EPO remained unchanged whereas reticulocyte count
was reduced by 25%-37% from day 7 to 21. sTfR
declined progressively after reinfusion. The highest OFF-
hr score was 126 at day 2 during the polycytemic period
corresponding to a 1 in 1000 cut-off threshold. Evidence
Table 1. Hematological parameters after blood withdrawal and reinfusion.
Control Blood withdrawal Reinfusion
Days C 1 3 7 14 28 0 1 3 7 14 21
Hb, g/dL 14.8±0.2 12.8±0.3* 12.4±0.2* 12.8±0.3* 13.2±0.2* 14.3±0.2 15.4±0.3*† 16.0±0.2*† 15.4±0.3*† 14.9±0.3 14.7±0.2 15.0±0.2
Hct, % 42.9±0.6 36.3±0.9* 35.5±0.7* 36.9±0.7* 38.9±0.6* 41.9±0.5 45.4±0.8† 47.1±0.5*† 45.2±0.8† 44.0±0.5 43.4±0.5 43.6±0.6
ret, % 1.1±0.1 1.6±0.1 1.9±0.1 3.0±0.2* 2.7±0.1* 1.3±0.1 1.3±0.1 1.1±0.1 1.1±0.1† 0.8±0.1*† 0.8±0.1*† 0.9±0.1†
s-EPO, 7.9±0.9 33.3±3.6* 28.5±3.6* 20.7±1.9* 14.8±1.4 10.5±0.9 NA 5.4±1.0 NA 9.0±0.9 6.6±0.9 7.8±0.9
mIU/mL
sTfR, 17.5±1.3 17.2±1.7 19.0±2.5 23.9±3.1 28.3±3.3* 28.4±3.0* NA 33.3±3.7* NA 28.1±2.9* 25.9±2.6 20.9±2.0
nmol/L
OFF-hr 85±3 53±5 43±5 24±4 33±4 75±3 87±4 96±3 87±3 95±3 90±2 92±3
Values are means±SEM for 10 male subjects. Hb, hemoglobin concentration; Hct, hematocrit; ret, reticulocytes; s-EPO, serum erythropoietin;
sTfR, soluble transferrin receptors; NA, Not Available. *Significantly different from control (p<0.05). †Significantly different preinfusion value(p<0.05).
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indicates that the hematocrit within-subject biological
and seasonal variation in man shows a maximal relative
change of 15% within a 95% confidence interval i.e. a
change from 0.42-0.48.5 Data of a wider range of sports
also show within subject estimates of variance in [Hb] of
1.6 g/dL,6 which agree with a10% fluctuation found in
soccer players.7 In the present study, however, all 10 sub-
jects exceeded the normal variation, with [Hb] ranging
from 19-39%. Even when the control [Hb] value was
taken as the mean [Hb] value, 9 of 10 subjects exceeded
their individual upper limit based on a 7.5% addition to
their control [Hb] value (range 3.0-11.5%). Importantly,
alterations in other hematological biomarkers (s-EPO,
reticulocytes and sTfR) were observed at all times
through this investigation, suggesting that determination
of these biomarkers could be used as supportive evidence
for erythropoietic manipulations with acute [Hb] increas-
es of more than 7.5%.
At present, only two blood tests are available. To pro-
tect the health of the athlete, World Anti Doping Agency
has implemented an upper limit of 17.0 g/dL, which – if
exceeded – elicits a no start sanction. However, only one
subject in this study showed [Hb] values higher than 17.0
g/dL. When using the OFF-hr model of Gore et al. con-
structed to convey the use of rHu-EPO4, we observed
that none of the subjects demonstrated positive OFF-
scores, rendering this model ineffective detecting blood
doping.
In conclusion, autologous blood procedures induce a
clear pattern of accelerated erythropoiesis during the ane-
mic period. Within the limitations of the study, it is sug-
gested that variations in [Hb] exceeding 15% between
samples obtained in top ranked endurance athletes dur-
ing the anticipated anemic period and shortly before any
major competition would be indicative of autologous
blood manipulation.
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Figure 1 (left).. Hemoglobin ([Hb]), serum erythropoietin, reticulo-
cytes and serum transferrin receptors (sTfR) responses during the
4 weeks after blood withdrawal of 20% of subjects’ blood volume
(1.3±0.2 L) and during the 3 weeks after blood reinfusion of 0.8±2
L of packed RBCs. Blood samples were collected before the inves-
tigation (Control, C) and on day 0, 1, 3, 7 14, 21 and 28 after blood
withdrawal and on day 0, 1, 3, 7, 14 and 21 after reinfusion.
Horizontal lines illustrate control values. Data are means±SEM for
10 subjects. * Significantly different from control (p<0.05). †
Significantly different from preinfusion values (p<0.05).
17
16
15
14
13
12
11
10
9
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
40
35
30
25
20
15
10
5
0
40
35
30
25
20
15
10
He
m
og
lo
bi
n
(g
/d
L)
Er
yt
hr
op
oi
et
in
(m
IU
/m
L)
Re
ty
cu
lo
cy
te
s
(%
)
sT
fR
(n
m
ol
/L
)
Time (days)
0 10 20 30 40 50
Letters to the Editor
| 1008 | haematologica/the hematology journal | 2005; 91(7)
References
1. Pace N, Lozner EL, Consolazio WV, Pitts GC, Pecora LJ. The
increase in hypoxic tolerance of normal men accompanying
the polycythaemia induced by transfusion of erythrocytes.
Am J Physiol 1947;148:152-63.
2. Lasne F, De Ceaurriz J. Recombinant erythropoietin in urine.
Nature 2000; 405(6787):635.
3. Nelson M, Popp H, Sharpe K, Ashenden M. Proof of homolo-
gous blood transfusion through quantification of blood group
antigens. Haematologica 2003;88:1284-95.
4. Gore CJ, Parisotto R, Ashenden MJ, Stray-Gundersen J, Sharpe
K, Hopkins W et al. Second-generation blood tests to detect
erythropoietin abuse by athletes. Haematologica 2003;
88:333-44.
5. Thirup P. Haematocrit: within-subject and seasonal variation.
Sports Med 2003;33:231-43.
6. Sharpe K, Hopkins W, Emslie KR, Howe C, Trout GJ,
Kazlauskas R, et al. Development of reference ranges in elite
athletes for markers of altered erythropoiesis. Haematologica
2002;87:1248-57.
7. Malcovati L, Pascutto C, Cazzola M. Hematologic passport for
athletes competing in endurance sports: a feasibility study.
Haematologica 2003;88:570-81.
